Headquartered in 92 Park Drive, Abingdon·Fiscal year ends December·NASDAQ: IMCR·immunocore.com
About Immunocore
Immunocore is a commercial-stage biotechnology company developing T cell receptor (TCR) bispecific immunotherapies under its proprietary ImmTAX platform for cancer, infectious diseases and autoimmune diseases. Its revenue comes from KIMMTRAK (tebentafusp-tebn), a gp100-targeting TCR bispecific approved in 39 countries, including the U.S., EU, UK, Canada and Australia. KIMMTRAK treats HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma and is sold in the United States, Europe and international markets. The company is pursuing label expansion for KIMMTRAK into previously treated advanced cutaneous melanoma (Phase 3 TEBE-AM) and adjuvant uveal melanoma (EORTC Phase 3 ATOM). Its pipeline spans three platforms. ImmTAC oncology candidates include the PRAME-targeting brenetafusp, in Phase 3 PRISM-MEL-301 for first-line cutaneous melanoma and in trials for ovarian cancer, NSCLC and uveal melanoma, plus the half-life-extended IMC-P115C. ImmTAV candidates such as IMC-M113V aim at a functional cure for HIV. ImmTAAI tissue-specific PD-1 agonist candidates include IMC-S118AI for type 1 diabetes and IMC-U120AI for dermatological diseases such as atopic dermatitis. The company also runs the KIMMTRAKConnect patient access program in the U.S. Updated
Pre-Market Stock Futures: The futures are trading higher as we start the new trading week. There is an old saying, “Fool me once, shame on you; fool me twice, shame on me.”…
Immunocore is a commercial-stage biotechnology company developing T cell receptor (TCR) bispecific immunotherapies under its proprietary ImmTAX platform for cancer, infectious diseases and autoimmune diseases.